PI4K

Phosphatidylinositol 4 kinases;PI4 kinases



The phosphatidylinositol 4-kinases (PI4Ks) synthesize phosphatidylinositol 4-phosphate (PI4P), a key member of the phosphoinositide family. PI4P defines the membranes of Golgi and trans-Golgi network (TGN) and regulates trafficking to and from the Golgi.

In mammals there are four different PI4K enzymes, two type II enzymes (PI4KIIα and PI4KIIβ) and two type III enzymes (PI4KIIIα and PI4KIIIβ). PI4KIIIβ plays key roles in mediating lipid transport, cytokinesis, maintaining lysosomal identity, and in tandem with Rab GTPases plays key roles in regulating membrane trafficking. PI4KIIIβ is critical for mediating viral replication of a number of RNA viruses through the generation of PI4P enriched viral replication platforms. Small molecule inhibitors of PI4KIIIβ are potent anti-viral agents. Development of PI4KIIIβ as an effective drug target for anti-viral therapeutics requires the generation of highly potent and specific inhibitors.

PI4K Inhibitors & Modulators

BF738735

Cat. No.: HY-U00426

Bioactivity: BF738735 is a phosphatidylinositol 4-kinase III beta (**PI4KIIIβ**) inhibitor with an **IC_{50}** of 5.7 nM.

Purity: 99.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



BQR-695

(NVP-BQR695) Cat. No.: HY-18748

Bioactivity: BQR-695 is a **PI4KIIIβ** inhibitor with **IC_{50}**s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



KDU691

Cat. No.: HY-12912

Bioactivity: KDU691 is a **PI4K** inhibitor.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PI4KIII beta inhibitor 3

Cat. No.: HY-15679

Bioactivity: PI4KIII beta inhibitor 3 is a novel and high effective **PI4KIIIβ** inhibitor with **IC_{50}** of 5.7 nM.

Purity: 97.96%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg



PI4KIIIbeta-IN-10

Cat. No.: HY-100198

Bioactivity: PI4KIIIbeta-IN-10 is a potent **PI4KIIIβ** inhibitor with an **IC_{50}** of 3.6 nM.

Purity: 98.90%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



PI4KIIIbeta-IN-9

Cat. No.: HY-19798

Bioactivity: PI4KIIIbeta-IN-9 is a potent **PI4KIIIβ** inhibitor with an **IC_{50}** of 7 nM. PI4KIIIbeta-IN-9 also inhibits **PI3Kδ** and **PI3Kγ** with **IC_{50}**s of 152 nM and 1046 nM, respectively.

Purity: 98.16%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



PIK-93

Cat. No.: HY-12046

Bioactivity: PIK-93 is the first potent, synthetic **PI4K (PI4KIIIβ)** inhibitor with **IC_{50}** of 19 nM, and also inhibits **PI3Kγ** and **PI3Kα** with **IC_{50}** of 16 nM and 39 nM, respectively.

Purity: 99.13%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



T-00127_HEV1

Cat. No.: HY-108313

Bioactivity: T-00127_HEV1 is a **phosphatidylinositol 4-kinase III beta** (**PI4KB**) inhibitor with an **IC_{50}** of 60 nM.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg



UCB9608

Cat. No.: HY-112613

Bioactivity: UCB9608 is a potent, selective and orally active **PI4KIIIβ** inhibitor, with an **IC_{50}** of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a pot...

Purity: 99.12%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



UCT943

Cat. No.: HY-112435

Bioactivity: UCT943 is a next-generation Plasmodium falciparum **PI4K** inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an **IC_{50}** of 23 nM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg